
6WDWLVWLFDO$QDO\VLV3ODQ 

6WXG\&RGH 37'& 
(GLWLRQ1XPEHU  
'DWH -DQXDU\ 








$5DQGRPL]HG'RXEOH%OLQG7ZR7UHDWPHQW7ZR3HULRG&KURQLF
'RVLQJ:HHNV&URVV2YHU6LQJOH&HQWHU6WXG\WR(YDOXDWHW KH(IIHFWV
RI37DQG3ODFHER0',RQ6SHFLILF,PDJH%DVHG$LUZD\9ROXPHV DQG
5HVLVWDQFHLQ6XEMHFWV:LWK0RGHUDWHWR6HYHUH&23'







 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 1 of 40) 
 
 
STATISTICAL ANAL YSIS PLAN FOR 
STUDY PT010011 
 
 
Protocol Number: PT010011 
 
Investigational Drug 
and Drug Number: BGF MDI; PT010 
 
Indication: COPD 
Dosage Form/Dose: x BGF MDI 320/28.8 /9.6 Œºg ex-actuator 
 
PT010011 Protocol Title:  A Randomized Open-label, Sin gle-dose, Single-center, Crossover  
Study in Healthy Subjects to Assess the Relative Bioavailabilit y of PT010 Administered With 
and Without a Spacer, and With and Without Oral Charcoal 
 
 
Date of Issue: 16 Jan 2018  
Version: Version 1.0 
 
  
Statistical Analysis Plan
Protocol Nos.:  PT010011
Date:  16 Jan 2018
                                        (Page 2 of 40)
Signed Agreement on Statistical Analysis Plan 
FINAL SIGN-OFF SIGNATURES 
Primary Biostatistician 
and Peer Reviewer:
Author:
Approved by:
[CONTACT_397504]:
Statistical Analysis Plan
Protocol Nos.:  PT010011
Date:  16 Jan 2018
                                        (Page 3 of 40)
Approved by:
[CONTACT_397504]:
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 4 of 40) 
 
Change Log  
Version No. Effective Date Reason for the Change / Revision Supersedes 
 
   
  
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 5 of 40) 
 
 
TABLE OF CONTENTS 
1. INTRODUCTION .................................................................................................................. ................... 9  
2. STUDY OBJECTIVES AND ENDPOINTS ............................................................................................ 9  
2.1 STUDY OBJECTIVES  .............................................................. ............................................................... . 9 
2.1.1  Primary Objective ............................................. ............................................................... ..... 9 
2.1.2  Secondary Objective ........................................... ............................................................... ... 9 
2.2 STUDY ENDPOINTS  .............................................................. ............................................................... .. 9 
2.2.1  Pharmacokinetic Endpoints ..................................... ............................................................. 9  
[IP_ADDRESS]  Primary PK Endpoints .......................................... ............................................. 10  
[IP_ADDRESS]  Secondary PK Endpoints ........................................ ........................................... 10  
[IP_ADDRESS]  Other PK Endpoints ............................................ ............................................... 10  
2.2.2  Safety Endpoints .............................................. ............................................................... .... 10  
3. STUDY DESIGN AND ANALYTICAL  CONSIDERAT IONS ........................................................... 10  
3.1 STUDY DESIGN  .............................................................. ............................................................... ...... 10  
3.1.1  Overall Study Desi gn and Plan ................................. .......................................................... 11  
3.1.2  Prior, Concomitant, Prohibited Medications .................... .................................................. 12  
3.2 RANDOMIZATION AND BLINDING  .............................................................. ......................................... 12  
3.3 HYPOTHESIS TESTING  .............................................................. .......................................................... 13  
3.4 SAMPLE SIZE .............................................................. ............................................................... ......... 13  
3.5 STUDY PROCEDURES  .............................................................. ............................................................ 13  
3.6 SCHEDULE OF ASSESSMENTS ............................................................... ............................................... 13  
4. DATA AND ANALYTICAL QU ALITY ASSURANCE ...................................................................... 13  
5. ANALYSIS POPULATIONS .......................................................................................................... ....... 14  
5.1 POPULATION DEFINITIONS  .............................................................. ................................................... 14  
5.1.1  Safety Population ............................................. ............................................................... .... 14  
5.1.2  Pharmacokinetic (PK) Population ............................... ....................................................... 14  
5.2 POPULATIONS FOR ANALYSES  .............................................................. .............................................. 14  
6. SPECIFICATION OF ENDPOI NTS AND VARIAB LES ................................................................... 14  
6.1 DEMOGRAPHICS AND BASELINE CHARACTERISTICS  .............................................................. ............. 14  
6.2 PHARMACOKINETICS  .............................................................. ............................................................ 15  
6.3 SAFETY ASSESSMENTS  .............................................................. ......................................................... 15  
6.3.1  Physical Examination .......................................... ...............................................................  1 5 
6.3.2  Vital Si gns ................................................... ............................................................... ........ 16  
6.3.3  12-Lead Electrocardiogram ..................................... ........................................................... 17  
6.3.4  Clinical Laboratory Tests ..................................... .............................................................. 18 
6.3.5  Adverse Events ................................................ ............................................................... .... 20  
6.3.6  Urine Drug Screening/Alcohol Breath Testing ................... ................................................ [ADDRESS_500255] ................................................ ............................................................... .... 23  
6.3.8  Concomitant Medicatio ns/Treatments ............................ .................................................... [ADDRESS_500256] DISPOSITION AND ANALYSIS POPULATIONS  .............................................................. .......... 24  
7.3 DEMOGRAPHIC AND BASELINE CHARACTERISTICS  .............................................................. .............. 25  
7.3.1  Medical and Surgical History at Screening, Reproductive Status,  and Pregnancy Testing 25  
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 6 of 40) 
 
7.3.2  Prior and Concomitant Medications/Treatments .................. .............................................. [ADDRESS_500257] ................................................ ............................................................... .... 30  
7.5.8  Prior/Concomitant Me dications/Treatments ...................... ................................................. 30  
8. ANALYSES PERFORMED BEFORE  DATABASE CLOSURE ....................................................... 31  
9. CHANGES FROM METHODS PLANNED IN THE PROTOCOL .................................................. 31  
10. STATISTICAL SOFTWARE .......................................................................................................... ....... 31  
11. REFERENCES .................................................................................................................... .................... 31  
APPENDIX 1: DATA HANDLING RULES ............................................................................................... ..... 31  
APPENDIX 2: TABLE OF CONTENTS FOR END-OF-TEXT TABLES, LISTINGS, AND FIGURES . 31  
APPENDIX 3: SAS CODE FOR ST ATISTICAL ANA LYSES ..................................................................... 40  
APPENDIX 4: CTCAE LABORATORY TEST CRITERIA FOR SHIFT TABLES AND CENTRAL 
LABORATORY REFERENCE RANGES FOR USE IN FLAGGING ABNORMAL VALUES .... [ADDRESS_500258] of Figures 
 
Figure 1  Study Design .................................................. ........................................................ 11  
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 7 of 40) 
 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
AE Adverse event 
ATC Anatomic Therapeutic Class 
AUC 0-tlast Area under the plasma concentration-time curve from [ADDRESS_500259] Measurable Plasma Concentration 
AUC 0-‚àû Area under the plasma concentrat ion-time curve from 0 Extrapola ted to 
Infinity 
BDRM Blinded Data Review Meeting 
BGF MDI Budesonide, Glycopyrronium, and F ormoterol Metered Dose Inhaler  
BLOQ Below Limit of Quantification 
BP Blood Pressure 
CI Confidence Interval 
CL/F Apparent Total Body Clearance 
Cmax Maximum Observed Plasma Concentration 
COPD Chronic Obstructive Pulmonary Disease  
CRF Case Report Form 
DMP Data Management Plan 
ECG Electrocardiogram 
eCRF Electronic Case Report Form 
eg Exempli gratia; for example 
GFR Glomerular Filtration Rate 
HR Heart Rate 
IB Investigators Brochure  
ICF Informed Consent Form 
i.e. Id Est; That Is 
Œªz Apparent Terminal Elimination Rate Constant  
LLOQ Lower Limit of Quantification 
MDI Metered dose inhaler 
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 8 of 40) 
 
MedDRA Medical Dictionary for Regulatory Activities 
Œºg Microgram 
mL Milliliter 
mm Millimeter 
mmHg Millimeter of mercury 
msec Millisecond 
NCA Non-Compartmental Analysis 
OTC Over-the Counter 
PCS Potentially Clinically Significant 
PK Pharmacokinetics  
PT Preferred Term 
PT010  Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation 
Aerosol 
QTcF QT Corrected Using Fridericia‚Äôs Formula  
SAE Serious adverse event 
SAP Statistical Analysis Plan 
SOC System Organ Class 
SOP Standard Operating Procedure  
t1/[ADDRESS_500260] measurable plasma concentration 
tmax Time To Maximum Observed Plasma Concentration  
Vd/F Apparent Volume of Distribution 
VS Vital signs 
WHO World Health Organization 
WHO-DD World Health Organization-Drug Dictionary 
WHO-DDE World Health Organization-Drug Dictionary Enhanced 
WHO-HD World Health Organization-Herbal Dictionary 
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 9 of 40) 
 
1. INTRODUCTION 
This Statistical Analysis Plan ( SAP) outlines the statistical m ethods for the display, summary and 
analysis of data to be performed at the end of Pearl Therapeuti cs, Inc. (Pearl) Study PT010011. 
The SAP should be read in conjunction with the study protocol. This version of the SAP has 
been developed using the PT010011 Protocol (Version 1.0 dated 1 1 September 2017) and the 
CRF Revision 01 dated 07 November, 2017. T his is the main SAP, describing the statistical 
analyses that will be carried out at the end of the study.  
This is a phase I, randomized, open label, single-dose, single center, crossover study to assess the 
pharmacokinetics (PK) and safety of budesonide, glycopyrronium,  and formoterol metered dose 
inhaler (BGF MDI) in healthy subjects. 
The definitions of data sets will  be described in separate docu ments called SDTM specifications 
and ADaM specifications.  
2. STUDY OBJECTIVES AND ENDPOINTS 
2.1 Study Objectives  
2.1.1 Primary Objective  
The primary objectives of this study are the following: 
x To assess the total systemic e xposure of budesonide, glycopyrro nium, and formoterol 
administered as BGF MDI with and without a spacer device 
x To assess the lung exposure of budesonide, glycopyrronium, and formoterol administered as 
BGF MDI with and without oral activated charcoal 
 
2.1.2 Secondary Objective 
The secondary objectives of this study are the following: 
x To characterize the PK profiles of budesonide, glycopyrronium, and formoterol administered 
as BGF MDI, with and without a spacer device, and with and with out oral charcoal 
x To assess the safety of single doses of BGF MDI in healthy subj ects 
 
2.2 Study Endpoints 
2.2.1 Pharmacokinetic Endpoints 
Pharmacokinetics after single-dose administration of BGF MDI wi ll be assessed using plasma 
concentrations of budesonide, glycopyrronium, and formoterol fo r each regimen.  
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 10 of 40) 
 
[IP_ADDRESS]  Primary PK Endpoints 
x Maximum observed plasma concentration (C max) 
x Area under the plasma concentration-time curve from [ADDRESS_500261] measurable 
plasma concentration (AUC 0-tlast) 
[IP_ADDRESS]   Secondary PK Endpoints 
x Time to maximum observed plasma concentration (t max) 
x Area under the plasma concentrat ion-time curve from 0 extrapola ted to infinity (AUC 0-‚àû) 
[IP_ADDRESS]  Other PK Endpoints 
x Apparent terminal elimination half-life (t 1/2) 
x Apparent total body clearance (CL/F) 
x Apparent volume of distribution (Vd/F) 
x Apparent t erminal elimination rate constant ( Œªz) 
x Time to last measurable plasma concentration (t last) 
2.2.2 Safety Endpoints 
x Adverse events (AEs) 
x 12-lead electrocardiograms (ECGs) 
x Clinical laboratory testing 
x Vital sign (VS) measurements 
3. STUDY DESIGN AND ANALYTICAL CONSIDERATIONS 
3.1 Study Design 
This is a Phase I, randomized, open-label, single-dose, single- center, crossover study to assess 
the PK and safety of BGF MDI in healthy subjects (male or femal e). The PK profiles of each 
active ingredient (budesonide, glycopyrronium, and formoterol),  will be determined after 
administration of BGF MDI with a spacer device (test) and witho ut a spacer device (reference), 
and with and without concomitant ad ministration of activated or al charcoal to estimate lung 
exposure and total systemic exposure, respectively. 
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 11 of 40) 
 
Approximately [ADDRESS_500262] within 5 to 7 days following the las t administration of BGF MDI. 
3.1.1 Overall Study Design and Plan 
The overall study design is summ arized and illustrated in Figur e 1. 
Figure 1 Study Design 
 
 
After providing informed  consent, subjects will undergo screeni ng procedures. Subjects meeting 
eligibility criteria will be enrolled into the study and admitt ed to the study site as an inpatient on 
Day -1 of Treatment Period 1, at which time continuing eligibil ity will be assessed. Device 
training will be conducted during screening, on admission to ea ch Treatment Period, and prior to 
dosing on Day 1 of each Treatment Period. In addition to traini ng with a placebo MDI device, 
additional inhalation training t ools may be used to help ensure  the subjects are able to use the 
MDI device correctly. 
Study drug will be administere d, under fasted conditions, on th e morning of Day 1 of each 
Treatment Period, at approximatel y the same time of day through out the study (¬± 30 minutes). 
Eligible subjects will receive a single dose of BGF MDI 320/28. 8/9.6 Œºg administered as 
follows: 

 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 12 of 40) 
 
x Without a spacer device and without charcoal (regimen A) 
x With a spacer device and wit hout charcoal (regimen B) 
x Without a spacer device and with charcoal (regimen C) 
x With a spacer device and with charcoal (regimen D) 
Subjects will receive all 4 regi mens (1 regimen per Treatment P eriod) in 1 of 8 possible regimen 
sequences: AB CD, AB DC, BA CD, BA DC, CD AB, CD BA, DC AB, or DC BA. 
The regimen sequences allow for subjects who might drop out aft er completing only [ADDRESS_500263] dosing (Day 1, Treatment Period 1). 
Randomization codes will be assign ed strictly sequentially in a scending order as subjects become 
eligible. 
During their inpatient stay, s ubjects will undergo safety asses sments and have an indwelling 
intravenous cannula for serial PK blood draws. Subjects will be  discharged on the morning of 
Day [ADDRESS_500264]. 
3.1.2 Prior, Concomitant, Proh ibited Medications 
Apart from paracetamol/acetaminophen, hormone replacement thera py and systemic 
contraceptives, no concomitant med ication or therapy will be al lowed. The subjects should be 
instructed that no other medication is allowed, including herba l remedies, vitamin supplements 
and over the counter (OTC) produc ts, without the consent of the  Investigator. 
When any medication is required, it should be prescribed by [CONTACT_16032]. Following 
consultation with the Medical Monitor, the Investigator must de termine whether or not the 
subject should continue in the study. 
The Investigator or designated qualified personnel will assess and record concomitant 
medication usage on the eCRF. Concomitant medication usage will  be assessed at screening and 
throughout the study. 
3.[ADDRESS_500265]-order 
Statistical Analysis Plan
Protocol Nos.:  PT010011
Date:  16 Jan 2018
                                        (Page 13 of 40)
carryover effects. Thus eligible subjects will be equally rando mized to 1 of the following 8 
regimen sequences: AB CD, AB DC, BA CD, BA DC, CD AB, CD BA, DC  AB, or DC BA. 
3.3 Hypothesis Testing 
No formal hypothesis tests will be performed for this study. 
3.4 Sample Size 
This study is being conducted for estimation purposes. 
 a sample size of 48 subjects completing the study will provide  
 probability to observe a 1-sid ed  lower confidence bound for t he geometric mean ratio 
(D/C) that is greater than  
3.5 Study Procedures 
Study procedures are contained in Table 8-1, Table 8-2, and Tab le 8-3 and detailed in Section 7 
and Section 8 of the study protocol. 
3.6 Schedule of Assessments 
A schedule of events for screen ing, treatment, and follow-up is  provided in Table 8-1 of the 
study protocol. Detailed schedules  of inpatient assessments on Day 1 during inpatient treatment 
periods 1, 2, and 3 are provided in Table 8-2 and inpatient ass essments on Day 1 during inpatient 
treatment period 4 are provided in Table 8-3, of the study prot ocol. 
4. DATA AND ANALYTICAL QUALITY ASSURANCE 
The overall quality assurance (Q A) procedures for the study dat a, statistical programming and 
analyses are described in Standard Operating Procedures (SOPs) of Everest Clinical Research. 
Detailed data management procedures are documented in the study  Data Management Plan 
(DMP), Data Validation Check Sp ecifications, and Integrated Saf ety Data Review Plan. Detailed 
statistical and programming quality control and quality assuran ce procedures are documented in 
the Statistical Analysis and Programming QC/QA Plan. 
The study endpoints and analytic approaches are both prospectiv ely defined and documented in 
the protocol and in this SAP. The SAP will be finalized, and pr otocol deviations will be 
identified and decisions for inclusion and exclusion of subject s from the PK Population will be 
made at the Blinded Data Review  Meeting (BDRM) prior to the dat abase lock and data analysis. 
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 14 of 40) 
 
5. ANALYSIS POPULATIONS 
5.[ADDRESS_500266] one dose of 
BGF MDI.  
Safety and tolerability analys es will be performed on data from  all subjects in the Safety 
Population. Analyses will be according to treatment received.  
5.1.2 Pharmacokinetic (PK) Population 
The PK Population is defined as all subjects in the Safety Population set for who m at least one 
of the primary PK parameters for a  given analyte can be calcula ted and who have no important 
protocol deviations thought to impact the analysis of the PK da ta. Major protocol deviations can 
result in exclusion of all data from a particular subject from the PK Population or require 
exclusion of data from a specifi c analyte, timepoint and/or sub sequent timepoints for an 
endpoint. Protocol deviations  for exclusion of subjects or data  from the PK Population will be 
agreed by [CONTACT_397505].  
Reasons for exclusion from the PK Population will documented in  the BDRM minutes prior to 
database lock; these minutes will be included in an appendix to  the Clinical Study Report. 
 
Pharmacokinetic analyses will be performed on data from all sub jects in the PK Population. 
Analyses will be according to treatment received.  
5.[ADDRESS_500267] eristics will be summarized de scriptively for both the PK and 
Safety Populations. Extent of ex posure will also be summarized for the Safety Population. For 
the PK Population, descriptive statistics without model adjustm ent will be used to describe the 
budesonide, glycopyrronium, and formoterol PK parameters by [CONTACT_397506]. The Safety Population 
will be used to summarize safety . Safety and tolerability analy ses will be based on descriptive 
statistics for vital signs, and laboratory measurements as appr opriate, and als o on frequencies of 
AEs (including any AEs based on ECG findings) as well as the nu mber and proportion of 
subjects with AEs.  
6. SPECIFICATION OF ENDPOINTS AND VARIABLES 
6.1 Demographics and Baseline Characteristics 
General demographic information such as age, race, ethnicity, g ender, weight, and height will be 
collected at the Screening visi t. Age will be calculated as the  integer part of (Informed Consent 
date ‚Äì Birth date)/365.25. For additional details please refer to the  Data Handing rules outlined in 
Appendix 1. 
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 15 of 40) 
 
Medical/surgical history will be collected on the eCRF during t he Screening period. Medical 
history will be coded using the latest version of the Medical D ictionary for Regulatory Activities 
(currently MedDRA 20.1).  
The definitions for the derived de mographic or baseline charact eristic variables can be found in 
Appendix 1. 
6.[ADDRESS_500268]-dose on Day 1 of each treatment perio d. See Section 7.4. 
6.3 Safety Assessments 
6.3.1 Physical Examination 
Any clinically significant physical examination abnormality rep orted after the start of study 
medication will be reported as a n adverse event. These adverse events will be included in the AE 
summaries.  
The physical examination will include:  
x Documentation of height (Screening only) 
x Documentation of weight (Screening only) 
x General appearance 
x Head, eyes, ears, nose, throat , and neck (including thyroid),  
x Respi[INVESTIGATOR_696] 
x Cardiovascular 
x Musculoskeletal 
x Abdominal 
x Neurologic 
x Extremities 
x Dermatologic 
x Lymph nodes 
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 16 of 40) 
 
6.3.2 Vital Signs 
Vital sign determinations, including blood pressure (BP) and he art rate (HR) will be performed 
after the subject has been supi[INVESTIGATOR_114926] a 5-minute period at the Screening Visit, on the day of each 
clinic admission (Day -1), on Day 1 prior to study drug adminis tration, and on Day 2 of 
Treatment Period 4.  
Potentially clinically significant (PCS) changes in systolic an d diastolic blood pressure  will 
be defined based on the criteria listed in Table 1.   
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 17 of 40) 
 
Table 1 Potentially Clinically Significant Criteria for Systoli c and Diastolic Blood Pressure 
Parameters 
Parameter (mmHg) Post-Baseline Criteria 
Systolic Blood Pressure, increase ‚â•180 mmHg and increase from 
baseline ‚â•20 mmHg  
Systolic Blood Pressure, decrease ‚â§90 mmHg and ‚â•20 mmHg decrease 
from baseline 
Diastolic Blood Pressure, increase ‚â•105 mmHg and increase from 
baseline ‚â•15 mmHg  
Diastolic Blood Pressure, decrease ‚â§50 mmHg and ‚â•15 mmHg decrease 
from baseline 
 
Potentially clinically significant changes in HR will be assess ed as follows: 
Table [ADDRESS_500269]-Baseline Criteria 
Tachycardia Event ‚â•110 bpm and increase ‚â•15% from baseline  
Bradycardia Event ‚â§50 bpm and decrease ‚â•15% from baseline  
 
6.3.3 12-Lead Electrocardiogram 
A Clinically Significant Abnormality  for a 12-Lead ECG measurement identified by [CONTACT_54117] a clinically significant abnormality will be re corded as an AE if it occurred after 
the start of study treatment. These adverse events will be incl uded in the AE summaries.  
All 12-Lead ECG measurements for the Safety Population will be listed . 
Potentially clinically significant ECG parameter values will be  identified based on criteria listed 
in Table 3.  
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 18 of 40) 
 
Table [ADDRESS_500270]-Baseline Criteria  
QTcF Prolongation  (1) ‚â• 500 msec if < 500 msec at study baseline and ‚â• 15 msec 
change from study baseline  
 
 (2) ‚â• 530 msec if ‚â• 500 msec at study baseline and ‚â• 15 msec 
change from study baseline 
 (3) ‚â• 500 msec  and ‚â• 15 msec change from study baseline  
 (4) Change of ‚â•60 msec from study baseline regardless of initial 
value 
msec = millisecond 
6.3.4 Clinical Laboratory Tests 
Laboratory testing (hematology with differential, chemistry and  urinalysis) will be performed 
using standard methods. The laboratory parameters to be assesse d in this study are listed below 
in Table 4. 
Potentially Clinically Significa nt Laboratory Values Above/Belo w a Clinically Relevant 
Threshold on-treatment, based on CTCAE 4.03 and other criteria, will be i dentified based on the 
thresholds in Table 5. 
  
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 19 of 40) 
 
Table [ADDRESS_500271] of Laboratory Tests 
Hematology Blood Chemistry 
Hematocrita 
Hemoglobin  
Platelet count  
Red blood cell (RBC) count  
White blood cell (WBC) count  
WBC differential  
Mean corpuscular volume (MCV) 
MCH concentration (MCHC)  Creatinineb 
Potassium (K+)  
Sodium (Na+)  
Chloride (Cl -) 
Magnesium (Mg++)  
Calcium  
Inorganic phosphate  
Glucose  
Urea  
Bilirubin (Total)  
 Bilirubin (direct) 
 Alanine aminotransferase 
    (ALT) 
 Aspartate aminotransferase   
    (AST) 
Gamma - 
   Glutamyltransferase 
   (GGT) 
Alkaline phosphatase  
Total Protein  
Albumin  
 
Urinalysis:  Macroscopic examination routinely including specific gravity, pH, protein, glucose, 
ketones, blood and urobilinogen. A microscopic examination will  be performed if warranted based 
on macroscopic results.  
Urine drug screen: A urine sample will be collected at screening and Day-1 of each  treatment 
period and analyzed (positive or negative) for drugs of abuse including amphetamine, opi[INVESTIGATOR_2573], 
cocaine, barbiturates, benzodiazepi[INVESTIGATOR_1651], cotinine, and marijuana  [tetrahydrocannabinol (THC)]. 
Alcohol Breathalyzer Test: A breathalyzer test will be performed at screening and Day -1 o f each 
treatment period for the presence of alcohol (positive or negat ive). 
Serology: Testing for HbsAg, Hepatitis C antibody, and HIV will be perfor med at screening only. 
Results of each serology test will be reported as either positi ve or negative.  
For females who are not post-menopausal: A serum hCG test at screening and urine hCG test at 
admission will be performed during each of the 4 Treatment Peri ods.  
For females of non-childbearing potential: A serum hCG test at screening will be performed. In 
addition, a serum FSH test for confirmation of non -childbearing status will be performed at 
screening.  
a Packed cell volume (PCV). 
b Serum creatinine value will be  used to calculate eGFR using Chr onic Kidney Disease Epi[INVESTIGATOR_345209] (according to National Kidney Disease Ed ucation Program) - CKD-EPI.  
 
Table 5 Potentially Clinically Significant (PCS) Laboratory Par ameter Criteria 
Parameter Post-Baseline Criteria 
Hematology  
Hemoglobin  <8.0 g/dL (<80 g/L) 
 Increase of >40 g/L to a value above the 
ULN 
White Blood Cell Count <2000/ŒºL 
 >35,000/ŒºL 
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 20 of 40) 
 
Parameter Post-Baseline Criteria 
Platelet Count <50,000/ŒºL 
 >999,000/ŒºL 
Chemistry  
eGFR-EPI  <30 mL/min/1.[ADDRESS_500272] >[ADDRESS_500273] 
ALT >[ADDRESS_500274] 
Alkaline Phosphatase >[ADDRESS_500275] 
Total Bilirubin >[ADDRESS_500276] 
Blood Glucose* (random values) <2.2 mmol/L (<39.6 mg/dL) 
 >13.9 mmol/L (>250 mg/dL) if baseline 
is below 10.0 mmol/L (180 mg/dL), > 16.7 mmol/L (>300 mg/dL) if baseline is greater than 10.0 mmol/L (180 mg/dL) 
Serum Potassium <3.0 mmol/L 
 >6.0 mmol/L 
*CTCAE 4.[ADDRESS_500277] prior to obtaining blood glucose values. 
6.3.5 Adverse Events 
Adverse events (AEs) will be col lected from the time of adminis tration of the first dose of study 
drug to the time of the Follow- Up Telephone Call Visit, study t ermination, or study exit. AEs 
will be characterized by [CONTACT_397507] g. The incidence of an AE will be 
defined by [CONTACT_397508].  
Adverse events will be collected and coded using the latest ver sion of MedDRA available at the 
time of database lock for this study. The study physician will review the adverse event coding. 
Adverse events that occur between the time the subject signs th e informed consent form for the 
study and the time when that subject receives the first dose of  study drug will be summarized as 
medical history and not as an AE unless the event meets the def inition of a serious adverse event 
(SAE). 
 
An AE is considered as On-Treatme nt if the onset date of the ad verse event is on or after the day of 
the first dose of randomized tre atment, and up to and including  the date completion of randomized 
treatment or the last day of premature withdrawal from randomiz ed treatment +[ADDRESS_500278] dose or if the time of AE  onset is unknown. All on-treatment 
AEs are refered to as treatment emergent adverse events (TEAEs) . 
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 21 of 40) 
 
An AE is considered as Post-tre atment if the onset date of the adverse event is after the date 
completion of randomized treatment or on or after the last day of premature withdrawal from 
randomized treatment +2 days.  
 
Adverse events will be listed in adverse event data listings ( Listing 7.1 ).  
Events with Irregular Start Dates : All adverse events will be included in the tabulations 
regardless of the completeness of the onset dates. 
Adverse events include, but are not limited to:  
x Any symptom or condition not previously reported by [CONTACT_423]  (medical history).  
x An exacerbation of a pre-existing symptom or condition.  
x A significant increase in frequency or intensity of a pre-exist ing epi[INVESTIGATOR_89274].  
x A drug interaction.  
x A condition first detected or diagnosed after study drug admini stration even though it 
may have been present prior to the start of the study.  
An AE does not include the following: 
x Medical or surgical procedures (e.g., surgery, endoscopy, tooth  extraction, blood 
transfusion); the condition that results in the procedure is co nsidered an AE (e.g., 
bleeding esophageal varices, dental caries).  
x Overdose of either study drug or concurrent medication without any clinical signs or 
symptoms.  
x Abnormal laboratory values that are not clinically significant.  (If accompanied by 
[CONTACT_23804]/symptoms, the signs or symptoms are considered an AE).  
An AE is considered ‚Äúserious‚Äù if, in the view of the Investigator or Sponsor, it results in any of 
the following outcomes:  
‚Ä¢ Death  
‚Ä¢ A life-threatening AE  
‚Ä¢ In patient hospi[INVESTIGATOR_397503].:  PT010011 
Date:  16 Jan 2018 
                                         (Page 22 of 40) 
 
‚Ä¢ A persistent or significant incapacity or substantial disruptio n of the ability to conduct 
normal life functions  
‚Ä¢ A congenital anomaly/birth defect.  
 
Important medical events that may not result in death, be life threatening, or require 
hospi[INVESTIGATOR_708], based upon appr opriate judgment, they may 
jeopardize the subject and may require medical or surgical inte rvention to prevent one of the 
outcomes listed in the definition. Examples of such medical eve nts include allergic 
bronchospasm requiring intensive t reatment in an emergency room  or at home, blood dyscrasias 
or convulsions that do not result in subject hospi[INVESTIGATOR_059], o r the development of drug 
dependency or drug abuse.  
Hospi[INVESTIGATOR_272] a pre-existing condition, including electiv e procedures, which has not 
worsened, does not constitute an SAE. 
An AE is considered ‚Äúlife -threatening‚Äô if, in the view of the Investigator or Sponsor, its 
occurrence places the subject at immediate risk of death. It do es not include an adverse reaction 
or suspected adverse reaction th at, had it occurred in a more s evere form, might have caused 
death.  
An AE or suspected adverse react ion is considered unexpected if  it is not listed in the current 
investigator brochure or is not listed at the specificity or se verity that has been observed. 
Many laboratory abnormalities  observed during the course of a s tudy will be included under a 
reported AE describing a clinica l syndrome (e.g., elevated BUN and creatinine in the setting of 
an AE of renal failure, or decreased hemoglobin in a case of bl eeding esophageal varices). In 
such cases, the laboratory abnormality itself (e.g., elevated c reatinine in a setting of renal failure) 
does not need to be recorded as a n AE. However, isolated labora tory abnormalities should be 
reported as AEs if they are considered to be clinically signifi cant by [CONTACT_737].  
Criteria for a "clinically significant" laboratory abnormality are:  
‚Ä¢ A laboratory abnormality that leads to a dose-limiting toxicity  (e.g., an abnormality that 
results in study drug dose reduction, suspension, or study with drawal)  
‚Ä¢ A laboratory abnormality that results in any therapeutic interv ention (e.g., concomitant 
medication or therapy)  
‚Ä¢ Other laboratory abnormality judged by [CONTACT_63033] o f any particular clinical 
concern (e.g., significant fall in hemoglobin not requiring tra nsfusion) 
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 23 of 40) 
 
For laboratory abnormalities that do not meet the above criteri a but are outside of normal range 
(e.g., < or > normal reference range), the Investigator should indicate whether the value is 
potentially clinically significant or not clinically significan t for the subject. 
6.3.6 Urine Drug Screening/Alcohol Breath Testing 
A urine sample will be collecte d and analyzed (positive or nega tive) for drugs of abuse including 
amphetamine, opi[INVESTIGATOR_2573], cocaine, barb iturates, benzodiazepi[INVESTIGATOR_1651], an d marijuana 
[tetrahydrocannabinol (THC)]. A breathalyzer test will be perfo rmed for the presence of alcohol 
(positive or negative). Both tests  will be conducted at Screeni ng and at inpatient admission days. 
6.3.[ADDRESS_500279] for confirmation of non-chi ldbearing status will be pe rformed at screening.  
 
6.3.8 Concomitant Medications/Treatments 
Concomitant medications will be  collected for for all visits of  the study. 
Any medications that were being taken prior to signing the ICF will be documented as prior 
study medications and must be stopped prior to entry. 
Concomitant medications will be coded using the latest version of the World Health 
Organization (WHO) Drug Dictionary Enhanced (WHO DDE) and the W HO Herbal Dictionary 
(WHO-HD). 
7. STATISTICAL ANALYSIS 
All data collected on the CRF a nd contributing to the analysis will be provided in listings, except 
for data collected only for confirmation of study entry criteri a and for study management 
purposes.  
All PK and safety parameters will be summarized unless specifie d otherwise.  
Continuous variables will be summarized with descriptive statis tics: the number of non-missing 
values, mean, standard deviation, median, minimum, and maximum.   
Categorical variables will be s ummarized with frequency counts and percentages (where 
appropriate). 
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 24 of 40) 
 
7.1 Data Handling Rules and Definiti ons, Including Handling of Miss ing Data 
Missing data will be maintained as missing in the analysis data sets, unless specified otherwise. 
For variables where missing data are imputed, the analysis data set will contain a new variable 
with the imputed value, and the original variable value will be  maintained as missing. 
Data imputation for PK summar ies is detailed in Section 7.4. 
Data Imputation for Adverse Events Summaries by [CONTACT_397509], an AE with missing severity w ill be deemed as severe. For 
AEs that c ould be associated with any study procedure the causal relationship is implied as ‚Äòyes‚Äô. 
Imputed values will not be listed in data listings.  
Data Imputation for Laboratory, Vital Sign, and ECG Summaries ( Continuous Parameters) 
By-visit and by-timepoint summaries will be based on scheduled visits and/or timepoints (i.e. no 
time windows), as applicable. Data from unscheduled visits and/ or timepoints will not be used 
for by-visit or by-timepoint summaries but will be included in the listings. Data from both 
scheduled and unscheduled visits w ill be used for shift tables and for determining incidence of 
clinically significant values. End-of-treatment refers to the l ast visit during study treatment when 
an assessment was made. 
Data Imputation (All Laboratory Summaries) 
Laboratory values of ‚Äò>=x‚Äô or ‚Äò<=x‚Äô will be taken as the value of x in the analyses. If a 
laboratory value is prefixed with‚Äò>‚Äô: the availa ble original value [PHONE_8263] will be used for table 
summaries; if a laboratory value is prefixed with ‚Äò<‚Äô, then  the original value ‚Äì0.[ADDRESS_500280] Disposition and Analysis Populations 
A disposition table for all s ubjects randomized will be provide d (Table 1.1 ). This tabulation will 
include the number and percentage of subjects who were treated with the study treatment, who 
completed the study, who withdrew from the study prematurely (e arly termination) along with 
the reason for study withdrawal. The number and percentage of s ubjects included in the Safety 
and PK Populations will also be tabulated by [INVESTIGATOR_24858] ( Table 1.3 ). Informed consent is listed in 
Listing 1.1 .  
A summary of reasons for withdrawal from study treatment by [CONTACT_397510] (Table 1.2).  These reasons will be listed in Listing 1.2 .  
Statistical Analysis Plan
Protocol Nos.:  PT010011
Date:  16 Jan 2018
                                        (Page 25 of 40)
7.3 Demographic and Baseline Characteristics 
Demographic data will be summarized for both the Safety and PK Populations (Tables 1.4.1 and 
1.4.2). Continuous demographic and baseline variables will be s ummarized by [CONTACT_397511], mean, standard deviation (SD), median, mini mum, and maximum values. 
For categorical demographic and baseline variables, the frequen cy and percentage of subjects 
will be tabulated. Demographic data will be listed (Listing 1.1 ). Medical and Surgical History 
(Listing 4.2) will be listed.  
Demographic variables summarize d will include the following: 
xAge 
xGender 
xRace  
xEthnicity 
xSmoking Classification (Smoking status - including number of ye ars smoked, time in years 
since last smoked, average number of cigarettes smoked per day)  
xWeight (kg) 
xHeight (cm) 
xBMI (body mass index, derived from weight and height, equal to weight in kg divided by [CONTACT_397512] m) 
7.3.[ADDRESS_500281]‚Äôs family health history, history of hospi[INVESTIGATOR_059], and history of surgeries. 
Medical and Surgical History at Screening will be listed for al l subjects (Listing 4.2) .  
Screening Reproductive Status and Pregnancy Testing Results wil l be listed (Listing 10.4) . 
7.3.2 Prior and Concomitant Medications/Treatments
Coding: Verbatim medication/treatmen t terms will be coded by  [CONTACT_397513] a preferred term and an ATC (anatomic therapeu tic class) term using the latest 
version of the World Health Organ ization Drug Dictionary (WHO-D D) available (version: 3Q 
2017 or later). 
Multiple ATC assignments:  If there are multiple ATC codes assigned to the same concomita nt 
medication, the ‚Äúprimary‚Äù one based on medical evaluation by [CONTACT_397514]. All 
Statistical Analysis Plan
Protocol Nos.:  PT010011
Date:  16 Jan 2018
                                        (Page 26 of 40)
prior medication taken by [CONTACT_2690] [ADDRESS_500282] while on study will be  recorded in the eCRF. 
Prior medication/treatment is any medication/treatment taken prior to study treatment, eve n if 
this medication continued to be taken on the day of the start o f study treatment in the study or 
afterward (Appendix 1) .
Concomitant medication/treatment is any medication/treatment reported as being taken after 
the start of the study treatmen t in the study and being taken o n or before the date prior to 
completion of or withdrawal from s tudy treatment for the subjec t. A medication with an onset 
date on or after the date of study  withdrawal from or completion  of randomized study treatment 
for the subject will not be considered concomitant, but will be  considered a Post-Treatment 
medication/treatment .
Any medication/treatment which cannot be identified as Prior, C oncomitant, or Post-Treatment 
will be considered as being in each of the categories that are possible from the available 
information. 
Reported prior, concomitant, and pos t-treatment medications wil l be listed (Listing 10.1.1 and 
Listing 10.1.2) .
7.3.[ADDRESS_500283] udy comments will be listed 
(Listing 10.5) .
7.[ADDRESS_500284]-dose at 2, 6, 20, and 40 minutes, and at 1, 2, 4, 8, 1 2, and 24 hours. 
Actual sampling time points relative to dosing will be used for  PK assessments and analysis 
where available. It is expected that the actual sampling time w ill generally be available. In any 
(likely rare) cases when the actual sampling time was not recor ded, the scheduled time may be 
used. This is considered preferable to ignoring a valid concent ration measurement. 
The concentration-time data repo rted by [CONTACT_397515]. 
The PK analysis will be performed for subjects in the PK Popula tion. 
PK parameters will be estimated by [CONTACT_105]-compartmental analysis ( NCA) using the software 
  
Statistical Analysis Plan
Protocol Nos.:  PT010011
Date:  16 Jan 2018
                                        (Page 27 of 40)
From the plasma budesonide, glycopyrronium and formoterol conce ntration-time data, the 
following PK parameters will be estimated for each subject wher e possible on Day 1 of each 
treatment period: 
AUC 0-tlast Area under the plasma concentration-time curve from [ADDRESS_500285] 
measurable plasma concentration
AUC 0-‚àû Area under the plasma concentrat ion-time curve from time 0 extr apolated to 
infinity
Cmax Maximum observed plasma concentr ation, expressed in concentrati on units
tmax Time to reach maximum observed plasma concentration (C max), expressed in hours
Œªz Terminal elimination rate constant , calculated from the slope o f the terminal 
portion of the ln(drug concentration) versus time curve
t1/2 Apparent terminal elimination half- life, expressed in hours, calculated as ln2/ Œªz
CL/F Apparent total body clearance
Vd/F Apparent volume of distribution
tlast Time to last measurable plasma concentration
AUC 0-tlast, and AUC 0-‚àû, will be calculated using the linear up/log down trapezoidal m ethod. 
The PK parameters C maxand time to C max(tmax) will be obtained from the observed values. 
Œªzwill be estimated for each subject  where feasible by [CONTACT_397516], calculated from 
the slope of the terminal por tion of the ln(drug concentration)  versus time curve. Selection of 
data points to include in the estimati on of Œªz for each subject for each analyte will be based on 
the following criteria: 
xAll samples used should preferably fall in the log-linear elimi nation phase. 
xAt least 3 samples above lowe r limit of quantification (LLOQ) s hould be used in the 
estimation. 
xCmaxmust not be used in the estimation. 
xAdjusted r2value reported in   must be ‚â• 0.8.
For the purposes of parameter estimation, plasma concentration values below the LLOQ will be 
set to missing in the NCA with t he exception of those values re ported at Day 1 pre-dose. Day 1 
pre-dose concentrations that ar e below the limit of quantificat ion (BLOQ) will be set to zero (per 
 SOP) for the NCA. Concentrations measured after the Day 1 dose  of study medication 
that are below the lower limit of quantification will set to mi ssing values (per SOP) for 
the NCA. Missing values (e.g., no blood sample collected, no va lue obtained at analysis) will be 
treated as missing and excluded from the NCA. If there are ‚â•2 consecutive missing conc entration 
values, the estimation of PK parameters will be evaluated on a case-by-case basis. 
For descriptive statistics for c oncentrations and for the conce ntration figures, all values below 
LLOQ will be assigned a value of ¬Ω LLOQ except for Day 1 pre-do se which will be assigned a 
value of 0 (no geometric mean will be calculated for Day 1 pre- dose). 
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 28 of 40) 
 
Descriptive statistics for plasma concentrations of budesonide,  glycopyrronium, and formoterol, 
by [CONTACT_397517]. Descriptive 
statistics will include the number of observations (n), mean (C V%), SD, standard error (SE), 
median, minimum (min), maximum (max), geometric mean, and geome tric coefficient of 
variation ( Tables 2.1.1, 2.2.1, and 2.3.1 ). The geometric coefficient of variation is calculated as 
GEOCV(y) (%) = 100*sqrt[(exp[var(ln[y])])-1], where sqrt is the  square root function and 
‚Äúvar(ln[y])‚Äù is natural -log scale variance.  
Descriptive statistics for PK parameters of budesonide, glycopy rronium, and formoterol, will be 
summarized by [INVESTIGATOR_24858]. Descrip tive statistics will include the number of observations (n), mean 
(CV%), SD, median, min, max, geometric mean, and geometric coef ficient of variation. For the 
PK parameters t max and t last, only the number of observations (n), mean, median, minimum (m in), 
and maximum (max) will be presented ( Tables 2.1.2, 2.2.2, and 2.3.2 ). 
The plasma concentration-time  profiles for individual and mean plasma concentrations of 
budesonide, glycopyrronium, and f ormoterol will be plotted for each treatment and each visit on 
the linear/linear scale and on the linear/log-linear scale for the Safety Population. 
Mean and individual plots will be separate for each analyte. No minal sampling time points 
relative to dosing will be used for all mean plots. Actual samp ling time points will be used for all 
individual plots (mean plots in  Figures 2.1.1 through  2.3.2 and individual plots in  Figures 2.4.1 
through  2.6.2 ). 
All concentration-time data reported by [CONTACT_397518], for each analyte, will be 
listed for subjects in the Safety Population ( Listing 8.1 ). Actual sample collection times will be 
detailed in the listing along with the scheduled nominal sample  collection times. In addition, all 
calculated PK parameters for each subject for each analyte will  be listed ( Listing 8.2 ). 
The treatment ratio of each of the test formulations (regimen B  or regimen D) will be compared 
to the reference formulations  (regimen A or r egimen C) for bude sonide, glycopyrronium, and 
formoterol. 
The statistical analysis will be conducted separately for the f ollowing: 
x Total systemic exposure: regimen B versus regimen A ( Table 2.1.3, Table 2.2.3, Table 
2.3.3 ) 
x Lung exposure: regimen D versus regimen C (Table 2.1.4, Table 2.2.4, Table 2.3.4) 
Treatment comparisons of primar y PK parameters will be assessed  on the difference of log-
transformed C max, AUC 0-tlast, and AUC 0-‚àû of budesonide, glycopyrronium, and formoterol using a 
2-sided 90% CI approach based on an a nalysis of variance model including period, sequence, 
regimen, and subject within seque nce as fixed effects. Estimate d geometric mean ratios with 
90% CIs will be provided. 
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 29 of 40) 
 
Only the data for the comparison under investigation will be in cluded in the statistical analysis, 
e.g., when comparing regimen B  and regimen A, the data for the other regimens will be removed 
from the dataset. Subjects must have a primary PK parameter ava ilable for both regimens for a 
given analyte under consideration in order to be included in a specific analysis. A subject may 
therefore be included in the a nalysis for one parameter and not  for another. 
To investigate the effect of the spacer on the PK parameters (A UC 0-tlast, AUC 0-‚àû and C max), 
summaries of the budesonide, glycopyrronium, and formoterol AUC 0-tlast, AUC 0-‚àû and C max 
pararmeters by [CONTACT_397519]. The quarti les are established based on 
values from without spacer only; t hen the AUC and Cmax values a nd the ratios for with:without 
spacer are summarized for each of the quartiles. 
Data will be divided into quartiles based on AUC 0-tlast reported during treatment without the 
spacer. 
7.5 Safety Assessments 
Safety data will be summarized by [CONTACT_397520]. The safety 
assessments for BGF MDI  will include AEs and SAEs, vital signs  (BP, HR), clinical laboratory 
values (hematology, chemistry , and urinalysis), and findings fr om 12-lead ECGs. The incidence 
of on-treatment AEs and SAEs w ill be tabulated. Summary statist ics of assessed laboratory 
values will also be tabulated. 
7.5.1 Physical Examination 
Any clinically significant physical examination abnormality rep orted after the start of study 
medication was to be reported as an adverse event. Thus, these will be included in listings of 
adverse events and summarized in adverse event summaries. 
7.5.2 Vital Signs 
Subjects with out-of-range values will be listed (Listing 10.2 ). All clinically significant 
abnormalities after administrat ion of randomized study drug wil l be reported as AEs. 
7.5.3 12-Lead Electrocardiogram 
Subjects with out-of-range values will be listed  (Listing 10.6 ). All clinically significant 
abnormalities after administrat ion of randomized study drug wil l be reported as AEs. 
7.5.4 Clinical Laboratory Tests 
Subjects with out-of-range hematology, chemistry, and urinalysi s results will be listed  ( Listings 
9.1 - 9.3 ). All clinically significant abnormalities after administratio n of randomized study drug 
will be reported as AEs. 
7.5.5 Adverse Events 
On-treatment AEs will be incl uded in tabular format, for subjec ts who meet the criteria for the 
Safety Population. Listings for AEs will present all AEs in the  database for all subjects ( Listings 
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 30 of 40) 
 
7.1 and 7.2 ). All AEs, whether on-treatment or not, will be included in th e Listings. Pre-
treatment SAEs will also be listed ( Listing 7.3) . 
Analysis endpoints for AEs include both the numbers of treatmen t-emergent AEs as observed by 
[CONTACT_397521], and the nu mbers of subjects experiencing 
treatment-emergent adverse events. The incidence of an on-treat ment AE will be defined as the 
number of subjects experiencing an event. 
An overall summary of subjects with at least one on-treatment A E, with AEs related to study 
treatment, with SAEs, with SAEs related to study treatment, wit h AEs leading to early 
withdrawal from the study, with SAEs leading to early withdrawa l from the study, and with 
deaths will be presented ( Table 3.1.1 ). 
The frequency and percentage of subjects experiencing a specifi c on-treatment AE will be 
tabulated by [CONTACT_9313] (SOC) and preferred term (PT) b y regimen for the Safety 
Population ( Table 3.1.2 ). 
On-treatment AEs will be summarized by (maximum) severity, with  respect to SOC and 
preferred terms by [INVESTIGATOR_24858] ( Tables 3.2.1 ). 
If applicable, deaths (PT) will be  included as part of AE/SAE a nalysis, including appropriate 
information such as date where available. 
Post-treatment AEs will be listed separately ( Table 3.1.3 and Tables 3.2.2 ). 
7.5.6 Urine Drug Screening and Alcohol Breath Testing 
Urine Drug Screening/Alcohol Breath Testing conducted during th e study will be provided in a 
listing ( Listing 10.3 ). 
7.5.[ADDRESS_500286] 
Pregnancy testing results conducted during the study will be pr ovided in a listing ( Listing 10.4 ). 
7.5.8 Prior/Concomitant Medications/Treatments 
Prior and concomitant medicati ons will be provided in a listing  (Listing 10.1.1 and Listing 
10.1.2 ). Information from both comple te and partial dates will be uti lized. Medications with end 
date of ‚ÄòOngoing‚Äô are considered concomitant. Should there not be sufficient information to 
determine whether a medication i s prior or concomitant the stat us will be considered to be both 
prior and concomitant. 
Concomitant medications and tre atments will be summarized for t he Safety Population. 
Frequency tables will present the frequency and proportion of s ubjects having received at least 
one concomitant medication during the course of the trial. Resu lts will also be summarized with 
respect to subjects‚Äô receiving medications by [CONTACT_397522] (Table 1.5.1). 
Statistical Analysis Plan
Protocol Nos.:  PT010011
Date:  16 Jan 2018
                                        (Page 31 of 40)
8. ANALYSES PERFORMED BEFORE DATABASE CLOSURE
Not applicable. 
9. CHANGES FROM METHODS PLANNED IN THE PROTOCOL  
This SAP outlines the statistical  methods for the display, summ ary and analysis  of data collected 
within the scope of Pearl Thera peutics Inc. Protocol PT010011, Version 1.0 dated 11 September 
2017.
10. STATISTICAL SOFTWARE 
 environment will be used for all statistical analyses.  
 will be used for all PK parameter 
calculations. 
11. REFERENCES 
 will be used for all PK parameter 
calculations. 
APPENDIX 1: DATA HANDLING RULES 
This appendix is provided in a separate document. 
APPENDIX 2: TABLE OF CONTENTS FOR END-OF-TEXT TABLES, LISTINGS, AND 
FIGURES 
[ADDRESS_500287] Disposition 
 (Analysis Set: All Subjects Randomized)  
Table 1.1.[ADDRESS_500288] Disposition  (Analysis Set: All Subjects Screened)  Table 1.2 Reasons for Withdrawal by [CONTACT_397523] 
 (Analysis Set: Safety Population)  
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 32 of 40) 
 
Table 1.3 Analysis Populations by [CONTACT_397523] 
 (Analysis Set: All Subjects Randomized)  Table 1.4.1 Summary of Demographic Data  (Analysis Set: Safety Population)  Table 1.4.2 Summary of Demographic Data  (Analysis Set: PK Population)  
Table 1.5.1 Summary of Concomitant Medications 
 (Analysis Set: Safety Population)  1.2 Pharmacokinetic Data 
Table 2.1.1 Descriptive Statistics for Plasma Concentrations of Budesonide (unit) by [CONTACT_397524] 
 (Analysis Set: PK Population)  
Figure 2.1.1 Mean (+/- SE) Plasma Budesonide Concentration-Time Profile after Single Dose 
Administration on Day 1 of each Trea tment Period (Linear-Linear Scale) 
(Analysis Set: PK Population)  
Figure [IP_ADDRESS] Mean (+/- SE) Plasma Budesonide Conc entration-Time Profile within 2 hours after Single 
Dose Administration (Linear-Linear Scale) 
(Analysis Set: PK Population)  
Figure 2.1.2 Mean Plasma Budesonide Concentration-Tim e Profile after Single Dose Administration (Log-
Linear Scale) 
(Analysis Set: PK Population) 
Table 2.1.2  Descriptive Statistics for Pharmacokinetic Parameters of Budesonide by [CONTACT_397523] 
(Analysis Set: PK Population)  
Table 2.1.3  Statistical Comparison of Budesonide PK Parameters ‚Äì Total Systemic Exposure (Without 
Charcoal) 
(Analysis Set: PK Population)  
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 33 of 40) 
 
Table 2.1.4  Statistical Comparison of Budesonide PK Parameters ‚Äì Lung Exposure  (With Charcoal) 
(Analysis Set: PK Population)  Table 2.1.5 Summary of Plasma Pharmacokinetic Pa rameters of Budesonide by [CONTACT_397525] 
(Analysis Set: PK Population)  
Table 2.2.1 Descriptive Statistics for Plasma Concen trations of Glycopyrronium (unit) by [CONTACT_397524] 
 (Analysis Set: PK Population)  
Figure 2.2.1 Mean (+/- SE) Plasma Glycopyrronium  Concentration-Time Profile after Single Dose 
Administration (Linear-Linear Scale) 
(Analysis Set: PK Population) 
Figure [IP_ADDRESS] Mean (+/- SE) Plasma Glycopyrronium  Concentration-Time Profile with 2 hours after 
Single Dose Administration (Linear-Linear Scale) 
(Analysis Set: PK Population) 
Figure 2.2.2 Mean Plasma Glycopyrronium Concentratio n-Time Profile after Single Dose Administration 
(Log-Linear Scale) 
(Analysis Set: PK Population)  
Table 2.2.2  Descriptive Statistics for Pharmacokine tic Parameters of Glycopyrronium by [CONTACT_397526] 
(Analysis Set: PK Population)  
Table 2.2.3  Statistical Comparison of Glycopyrro nium PK Parameters ‚Äì Total Systemic Exposure 
(Without Charcoal) 
(Analysis Set: PK Population)  
Table 2.2.4  Statistical Comparison of Glycopyrroni um PK Parameters ‚Äì Lung Exposure (With Charcoal) 
(Analysis Set: PK Population)  Table 2.2.5  Summary of Plasma Pharmacokinetic Para meters of Glycopyrronium by [CONTACT_397525] 
(Analysis Set: PK Population)  
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 34 of 40) 
 
Table 2.3.1 Descriptive Statistics for Plasma Conc entrations of Formoterol (unit) by [CONTACT_397524] 
 (Analysis Set: PK Population)  
Figure 2.3.1 Mean (+/- SE) Plasma Formoterol Concentration-Time Profile after Single Dose 
Administration (Linear-Linear Scale) 
(Analysis Set: PK Population)  
Figure [IP_ADDRESS] Mean (+/- SE) Plasma Formoterol Co ncentration-Time Profile with 2 hours after Single 
Dose Administration (Linear-Linear Scale) 
(Analysis Set: PK Population)  
Figure 2.3.2 Mean Plasma Formoterol Concentration-Tim e Profile after Single Dose Administration (Log-
Linear Scale) 
(Analysis Set: PK Population)  
Table 2.3.2  Descriptive Statistics for Pharma cokinetic Parameters of Formoterol by [CONTACT_397527] 
(Analysis Set: PK Population)  
Table 2.3.3  Statistical Comparison of Formoterol PK Parameters ‚Äì Total Systemic Exposure (Without 
Charcoal) 
(Analysis Set: PK Population)  Table 2.3.4  Statistical Comparison of Formoterol PK Parameters ‚Äì Lung Exposure (With Charcoal) (Analysis Set: PK Population)  Table 2.3.5  Summary of Plasma Pharmacokinetic Parameters of Formoterol by [CONTACT_397525] 
(Analysis Set: PK Population)  
Figure 2.4.1  Individual Plasma Concentration-T ime Profile of Formoterol after Single Dose 
Administration (Linear-Linear Scale) 
 (Analysis Set: PK Population)  
Figure 2.4.2  Individual Plasma Concentration-T ime Profile of Formoterol after Single Dose 
Administration (Log-Linear Scale) 
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 35 of 40) 
 
 (Analysis Set: PK Population)  
Figure 2.4.[ADDRESS_500289] after Single-Dose Administration with Charcoal 
(Analysis Set: PK Population)  Figure [IP_ADDRESS]  Invidual Budesonide AUC0-tlast af ter Single-Dose Administr ation without Charcoal 
(Analysis Set: PK Population)  Figure 2.4.4  Invidual Budesonide Cmax afte r Single-Dose Administration with Charcoal 
(Analysis Set: PK Population)  
Figure [IP_ADDRESS]  Invidual Budesonide Cmax aft er Single-Dose Administr ation without Charcoal 
(Analysis Set: PK Population)  Figure 2.4.5  Invidual Budesonide AUC0- ‚àû after Single-Dose Admini stration with Charcoal 
(Analysis Set: PK Population)  Figure [IP_ADDRESS]  Invidual Budesonide AUC0- ‚àû after Single-Dose Administ ration without Charcoal 
(Analysis Set: PK Population)  
Figure 2.5.1  Individual Plasma Concentration-T ime Profile of Formoterol after Single Dose 
Administration (Linear-Linear Scale) 
 (Analysis Set: PK Population)  
Figure 2.5.2  Individual Plasma Concentration-Tim e Profile of Formoterol after Single Dose 
Administration (Log-Linear Scale) 
 (Analysis Set: PK Population)  Figure 2.5.[ADDRESS_500290] after Single-Dose Administration with Charcoal 
(Analysis Set: PK Population)  
Figure [IP_ADDRESS]  Invidual Glycopyrronium AUC0-tlast after Single-Dose Administ ration without Charcoal 
(Analysis Set: PK Population)  
Figure 2.5.4  Invidual Glycopyrronium Cmax af ter Single-Dose Administration with Charcoal 
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 36 of 40) 
 
(Analysis Set: PK Population)  
Figure [IP_ADDRESS]  Invidual Glycopyrronium Cmax af ter Single-Dose Administr ation without Charcoal 
(Analysis Set: PK Population)  Figure 2.5.5  Invidual Glycopyrronium AUC0- ‚àû after Single-Dose Administration with Charcoal 
(Analysis Set: PK Population)  Figure [IP_ADDRESS]  Invidual Glycopyrronium AUC0- ‚àû after Single-Dose Administration without Charcoal 
(Analysis Set: PK Population)  
Figure 2.6.1 Individual Plasma Concentration-Tim e Profile of Formoterol after Single Dose 
Administration (Linear-Linear Scale) 
 (Analysis Set: PK Population)  
Figure 2.6.2  Individual Plasma Concentration-T ime Profile of Formoterol after Single Dose 
Administration (Log-Linear Scale) 
 (Analysis Set: PK Population)  
Figure 2.6.[ADDRESS_500291] af ter Single-Dose Administration with Charcoal 
(Analysis Set: PK Population)  Figure [IP_ADDRESS]  Invidual Formoterol AUC0-tlast af ter Single-Dose Administr ation without Charcoal 
(Analysis Set: PK Population)  Figure 2.6.4  Invidual Formoterol Cmax aft er Single-Dose Administration with Charcoal 
(Analysis Set: PK Population)  Figure [IP_ADDRESS]  Invidual Formoterol Cmax afte r Single-Dose Administration without Charcoal 
(Analysis Set: PK Population)  
Figure 2.6.5  Invidual Formoterol AUC0- ‚àû after Single-Dose Admini stration with Charcoal 
(Analysis Set: PK Population)  
Figure [IP_ADDRESS]  Invidual Formoterol AUC0- ‚àû after Single-Dose Administ ration without Charcoal 
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 37 of 40) 
 
(Analysis Set: PK Population)  
 1.[ADDRESS_500292] One Treatment Emergent Adverse Event 
 (Analysis Set: Safety Population)  
Table 3.1.2 Summary of On-treatment Adverse Even ts by [CONTACT_39960] 
 (Analysis Set: Safety Population)  Table 3.1.[ADDRESS_500293]-treatment Adverse Events by [CONTACT_39960] (Analysis Set: Safety Population)  
Table 3.2.[ADDRESS_500294] Severity by 
[CONTACT_397523] 
 (Analysis Set: Safety Population)  
Table 3.2.[ADDRESS_500295] Severity by 
[CONTACT_397523] 
 (Analysis Set: Safety Population)  
  
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 38 of 40) 
 
[ADDRESS_500296] Disposition and Demographic Data 
 (Analysis Set: All Subjects Randomized)  Listing 1.2 Listing of Early Withdrawals  (Analysis Set: Safety Population)  
2.1.2 Protocol Deviations 
Listing 2.1 Listing of Major Protocol Deviations 
 (Analysis Set: Safety Population)  Listing 2.2 Violation of Inclusion/Exclusion Criteria  (Analysis Set: All Subjects Treated)  2.1.3 Subjects Excluded from the Analysis Populations 
Listing 3.1 Listing of Subjects Ex cluded From Analysis Populations 
 (Analysis Set: Safety Population)  2.1.4 Baseline Characteristics 
Listing 4.2 Listing of Medical and Surgical History  (Analysis Set: Safety Population)  2.1.5 Dosing and Compliance 
Listing 5.1 Listing of Study Drug Dosing 
 (Analysis Set: Safety Population)  
  2.1.[ADDRESS_500297], System Organ Class, Preferred Term and Onset 
Day 
 
  Statistical Analysis Plan  
Protocol Nos.:  PT010011 
Date:  16 Jan 2018 
                                         (Page 39 of 40) 
 
 (Analysis Set: Safety Population)  
Listing 7.[ADDRESS_500298], System Organ Class, Preferred Term 
and Onset Day 
 (Analysis Set: All Screened Subjects)  
Listing 7.[ADDRESS_500299], System Organ Class, 
Preferred Term and Onset Day 
 (Analysis Set: Safety Population)  
2.1.7 Pharmacokinetic Data 
Listing 8.1 Plasma Concentrations of Budesonide, Glycopyrronium, and Formoterol by [CONTACT_397528], 
Regimen, Period, Study Day, and Timepoint 
(Analysis Set: PK Population)  
Listing 8.[ADDRESS_500300] ID 
(Analysis Set: PK Population)  
Listing 8.[ADDRESS_500301] ID 
(Analysis Set: PK Population)  2.1.[ADDRESS_500302] Results - Hematology 
 (Analysis Set: Safety Population)  Listing 9.[ADDRESS_500303] Results - Chemistry 
 (Analysis Set: Safety Population)  
Listing 9.[ADDRESS_500304] Results - Urinalysis 
(Analysis Set: Safety Population)  2.1.[ADDRESS_500305]-Treatment Medication (COPD Related) 
Statistical Analysis Plan
Protocol Nos.:  PT010011
Date:  16 Jan 2018
                                        (Page 40 of 40)
 (Analysis Set: All Subjects Screened)  
Listing 10.1.[ADDRESS_500306]-Treatment Medication (Non-COPD 
Related) 
 (Analysis Set: All Subjects Screened)  Listing 10.2 Listing of Out-of-Range  Vital Signs, Weight, and Height 
 (Analysis Set: All Subjects Screened)  
Listing 10.3 Listing of Urine Drug Screening / Alcohol Breath Testing 
 (Analysis Set: All Subjects Screened)  Listing 10.4 Listing of Pregnancy Testing  (Analysis Set: All Subjects Screened)  Listing 10.5 Listing of Comments  (Analysis Set: All Subjects Screened) Listing 10.6 Out-of-Range 12-Lead Electrocardiogram (ECG) 
 (Analysis Set: All Subjects Screened)  
APPENDIX 3:  CODE FOR STATISTICAL ANALYSES 
This appendix is provided in a separate document. 
APPENDIX 4: CTCAE LABORATORY TEST CRITERIA FOR SHIFT TABLES AND 
CENTRAL LABORATORY REFERENCE RANGES FOR USE IN FLAGGING ABNORMAL VALUES 
This appendix is provided in a separate document. 